Pharma Mirror

JANUARY 29, 2022

An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily. Shenzhen) and a local precision medicine research institute.

Antibody 130

Antibody Engineer Scientist Medicine 130

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.

Antibody 81

Antibody FDA Approval Drugs Development 81

Drug Discovery World

APRIL 15, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

Drug Discovery World

APRIL 8, 2024

Join DDW for this free event ‘ Where is the opportunity in the therapeutic antibody market? ’, which is co-sponsored by Bio-Rad and Benchling. Dr Milind Nigam will discuss the role of software in accelerating the pace of discovery of antibody therapeutics. What effect has antibody engineering had on drug discovery and development?

Antibody 52

Antibody Marketing Gene Therapy Engineer 52

Bio Pharma Dive

MARCH 29, 2022

The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.

Antibody 130

Antibody Medicine Drugs 130

Pharma Mirror

APRIL 18, 2023

Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Pharmaceutical Technology

MAY 8, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

Antibody 130

Antibody Drugs Development Medicine 130

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Pharmaceutical Technology

AUGUST 11, 2022

Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US. To back the merger, Disc raised funds worth $53.5m

Medicine 147

Medicine Clinical Trials Clinical Trials Licensing 147

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.

Antibody 130

Antibody Development Drugs Licensing 130

Drug Discovery World

JANUARY 4, 2024

Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. The post Ampersand Biomedicines acquires antibody discovery company appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Medicine Drugs 52

Pharmaceutical Technology

JULY 5, 2022

Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The post Sanofi unveils global health brand for medicines supply appeared first on Pharmaceutical Technology.

Branding 147

Branding Medicine Insulin Antibody 147

Bio Pharma Dive

APRIL 3, 2024

The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

Antibody 171

Antibody Medicine Development Drugs 171

Bio Pharma Dive

APRIL 14, 2023

Newly launched TORL BioTherapeutics wants to develop a variety of antibody drugs, and comes equipped with $158 million as well as a close partnership with the lab of pioneering breast cancer researcher Dennis Sloman.

Medicine 171

Medicine Antibody Development Drugs 171

STAT News

FEBRUARY 21, 2023

An experimental antibody that delivers lethal radiation directly to the bone marrow improved the outcomes of stem cell transplants for older patients with relapsed leukemia — and may change the way transplant medicine is practiced.

Antibody 105

Antibody Medicine Development 105

STAT News

AUGUST 3, 2022

An experimental antibody treatment prevented malaria in the majority of participants in a small but important new study , providing a measure of hope in the effort to lower the burden of the disease worldwide. Read the rest…

Antibody 105

Antibody Clinical Trials Clinical Trials Trials 105

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Bio Pharma Dive

FEBRUARY 15, 2024

Armed with $94 million in funding, the biotech is marrying antibody-drug conjugates with protein degraders to create a new kind of cancer medicine.

Protein 183

Protein Antibody Medicine Drugs 183

Medical Xpress

DECEMBER 2, 2022

The presence of food-specific IgA antibodies in the gut does not prevent peanut or egg allergies from developing in children, according to a Northwestern Medicine study published in Science Translational Medicine.

Allergies 81

Allergies Antibody Medicine Development 81

Medical Xpress

NOVEMBER 17, 2022

But a study by researchers at Stanford Medicine shows that old mice regain the leg muscle strength of younger animals after receiving an antibody treatment that targets a pathway mediated by a molecule called CD47.

Antibody 98

Antibody Medicine Research 98

Drug Discovery World

MARCH 8, 2024

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.

Antibody 52

Antibody Trials In-Vitro Clinical Trials 52

Bio Pharma Dive

JANUARY 8, 2024

The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

Drugs 183

Drugs Development Antibody Medicine 183

Bio Pharma Dive

APRIL 3, 2023

The biotech is expanding its cancer medicine pipeline by licensing two experimental antibody drug conjugates from Shanghai-based Duality.

Licensing 287

Licensing Licensing Antibody Medicine 287

Pharmaceutical Technology

MAY 24, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Recombinant viral vector-based medicinal preparations. However, not all innovations are equal and nor do they follow a constant upward trend.

Medicine 130

Medicine Vaccination Vaccine Gene 130

Scienmag

MARCH 21, 2022

An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar. 16 in Science Translational Medicine.

Antibody 79

Antibody Development Medicine Research 79

Bio Pharma Dive

DECEMBER 8, 2022

As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.

Drugs 323

Drugs Antibody Medicine Development 323

Scienmag

JUNE 27, 2022

A major clinical trial, led by experts at the University of Nottingham working in partnership with several Universities and NHS hospitals, has found that by interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination, their antibody response to the jab is doubled.

Antibody 60

Antibody Medicine Vaccination Vaccine 60

Medical Xpress

JANUARY 26, 2023

A monoclonal antibody treatment was found to be safe, well tolerated, and effective in protecting against malaria in a small group of healthy volunteers who were exposed to malaria in a challenge study, according to new research published in The Lancet Infectious Diseases by researchers at the University of Maryland School of Medicine (UMSOM).

Antibody 98

Antibody Medicine Research 98

Bio Pharma Dive

OCTOBER 20, 2022

The deal gives AbbVie an experimental medicine for idiopathic pulmonary fibrosis, as well as a platform for designing antibody drugs that can target proteins known as GPCRs.

Protein 321

Protein Antibody Medicine Drugs 321

Bio Pharma Dive

JULY 14, 2023

billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines. The pharma will pay up to $1.9

Antibody 246

Antibody Drugs Medicine 246

Bio Pharma Dive

MARCH 23, 2023

The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.

Trials 280

Trials Antibody Medicine Marketing 280

pharmaphorum

MAY 18, 2022

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on.

Antibody 88

Antibody Licensing Licensing Medicine 88

Drug Discovery World

JANUARY 25, 2024

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. Vaxxinity’s platform is designed to harness and selectively activate the immune system by overcoming immune tolerance, stimulating the production of antibodies against endogenous targets.

Medicine 52

Medicine Research In-Vivo In-Vitro 52

Scienmag

JUNE 15, 2022

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM).

Antibody 75

Antibody Medicine 75

Medical Xpress

FEBRUARY 27, 2023

Every four months, pathologist Aaron LeBeau scoops into a net one of the five nurse sharks he keeps in his University of Wisconsin lab. Then he carefully administers a shot to the animal, much like a pediatrician giving a kid a vaccine. The shot will immunize the shark against a human cancer, perhaps, or an infectious disease, such as COVID-19.

Antibody 98

Antibody Medicine Nurses Vaccination 98

Medical Xpress

NOVEMBER 9, 2022

A new approach to stem cell therapy that uses antibodies instead of traditional immunosuppressant drugs robustly preserves cells in mouse brains and has potential to fast-track trials in humans, a Michigan Medicine study suggests.

Antibody 98

Antibody Medicine Trials Drugs 98